Lactation suppression and puerperal fever.
Seventy-five puerperal women who did not wish to breast-feed were treated with bromocriptine mesylate (Parlodel) or placebo in a prospective, randomized, double-blind study. Results revealed a puerperal fever incidence of 18.6%, 13.3% of which was due to breast engorgement and 5.3% to an infectious process. Parlodel prevented puerperal fever in 87.9% of patients. If Parlodel was given within 18 hours of delivery, physiologic puerperal fever was prevented in 100% of cases.
D001971:Bromocriptine / Q000627:therapeutic use; D003864:Depression, Chemical; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D011247:Pregnancy; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000209:etiology / Q000517:prevention & control*; D011897:Random Allocation; D013997:Time Factors
D001971:Bromocriptine